Oramed Pharmaceuticals Inc. (ORMP) is a public biotechnology company based in Jerusalem, Israel. Oramed develops an orally ingestible capsule for the delivery of protein-based therapies to the blood circulation through the gastro-intestinal (GI) pathway, with focus on treatment of diabetes. The Company's business model is based on advancing in-house R&D projects, based on its proprietary drug delivery system, up to mid-stage clinical development, following which the company will aspire to sublicense specific products to major players in the pharmaceutical marketplace.
The company's stock was traded in the OTCQB market until Feb 8, 2013. On Jan 22, 2013, Oramed announced a one for twelve reverse stock split in order to help it meet the qualifications for listing its...
Only subscribers can access this article, which is part of the PRO research library covering 3,574 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: